MIGLIT
Brand:
MIGLIT
Manufacturer:
BIOCON
Manufacturer Details
BIOCON
Biocon Limited
20th KM Hosur Road
Electronic City P.O.
Bangalore 560 100
us@biocon.com
Compositions:
Miglitol 25mg/50mg tablets,
|
Strength
|
Rate
|
Packing Style
|
|
25mg
|
59.16
|
10s tablets
|
|
50mg
|
108.00
|
10s tablets
|
List of Related Indications:
- Type II Diabetes not respons to diet
List Of Drugs:
- Miglitol - Antidiabetic Agents- (FDC- List )- (Aug 2004)
Indication Type Description:
Drug Interaction:
Drug interactions - summary
Miglitol +
Propranol/ Ranitidine
decreased bioavailbility of propranol and rantidine
Fluconazole
increased levels/ effects of fluconazole
Salicylates / MAOIs, / Alcohol / NSAIDs,
increased hypoglycemic effects with salicyltes,MAOIs , alcohol, NSAIDs
Rifampicin
Decreased levels/effects with - rifampicin
Thiazide diuretics /Corticosteroids/ Thyroid products/ Sympathomimetics
Decreased hypoglycemic effects with thiazide diuretics,
corticosteroids, thyroid products and sympathomimetic agents
Indication:
LIST OF DRUGS DURING 2004
Sr.No- 224
Name of the Drug- Miglitol Tablet 25mg/50mg/100mg
Pharmacological Classification- Anti-diabetic
Date of Approval- 18-08-2004
Approved by U.S.FDA on 30-12-2004 (Ref- FDA approved List- 2004)
LIST OF DRUGS DURING 2007
Sr.No- 159
Name of the Drug- Miglitol 50mg +
Metformin HCL SR 500mg tablet
Pharmacological Classification- For adult with Type II with diabetes mellitus
where simple drug therapy, diet, and excercise
do not result in adequate glycemic control
Date of Approval- 31-10-07
Approved by U.S.FDA on 30-12-2007 (Ref- FDA approved List- 2007)
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Miglitol 50mg 31-10-2007
+ Metformin Hcl SR 500mg tablet
For Adult with Type II diabetes melitus where simple drug therapy,
diet and excercise do not result in adequate glycemic control
2.Miglitol 25mg 16-03-2010
+ Metformin 500mg tablets
Additional strength
Management of Type II diabetes
Adverse Reaction:
May cause gastrointestinal disturbances, including flatulance due to bacterial action on non-absorbed carbohydrate in colon Abdominal distention, diarrhea, and pain may occur
Decreased dosage of acrabose together with improved dietary habits may reduce adverse effects Hepatoxicity mau occur and may necessiate a redution in dosage or withdrawal of the drug
Skin reactions occur rarely
Contra-Indications:
Should be used with caution in patients with renal impairment
Dosages/ Overdosage Etc:
Indications-
Management of Type II diabetes
Dosage
Initial dose 25mg 3 times a daily with meals, increased if nrecessary to 100mg 3 times daily
